Exact Sciences Corporation (EXAS) is making robust efforts to further promote Cologuard as the standard of care, building on its established reputation. The company’s progress across its pipeline is highly encouraging, with several new solutions expected to debut in the market in the coming months. On top of this, its sound financial health bodes well. Yet, cost pressures from macroeconomic challenges and excessive reliance on its lead brand raise concerns for Exact Sciences.Meanwhile, surging costs from ma ...